Objective: To investigate the potential mechanisms of nonsteroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory analgesics against respiratory syncytial virus (RSV) through a network pharmacology approach. The most influential NSAIDs against RSV were screened through network pharmacology studies. Methods: NSAIDs (19 active drugs and one prodrug) approved by U.S. Food and Drug Administration (FDA) were used in this study. Targets for NSAIDs were collected through the Swiss Target Prediction and PubChem databases, and RSV targets were searched in the GeneCards database. The intersection of NSAIDs target proteins with RSV target proteins was mapped using Wayne's Web, protein interaction analysis of drug-disease intersection target proteins was performed in the STRING database, and the network was embellished using Cytoscape 3.9.0. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the intersecting target proteins was performed in the DAVID database. Bubble plotting for KEGG pathway enrichment analysis was made using the Bioinformatics drawing tool. Pathway-target-component network analysis was performed by Cytoscape 3.9.0. Finally, the binding affinity of NSAIDs to target proteins is determined by molecular docking (AutoDock Vina). Results: A total of 421 targets of NSAIDs, 391 targets associated with RSV, 39 overlapping target proteins were collected. 37 anti-RSV signaling pathways were revealed busing Genomic enrichment analysis. MAPK1, AKT1 and MAP2K1 were explored as the target proteins with the greatest relevance to the B-cell receptor signaling pathway. Conclusion: Three NSAIDs (sulforaphane, rofecoxib and diclofenac) may block the B-cell receptor signaling pathway by inactivating their related target proteins, thereby potentially alleviating RSV-induced bronchitis and pneumonia.
HOU Xianbang
,
HUANG Yujie
,
ZHANG Zijin
. Network pharmacological analysis of the anti-RSV mechanism of NSAIDs[J]. Journal of Baotou Medical College, 2024
, 40(10)
: 12
-18
.
DOI: 10.16833/j.cnki.jbmc.2024.10.003
[1] Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic[J]. Pediatrics, 2021, 148(3): e2021052089.
[2] Korsun N, Angelova S, Trifonova I, et al. Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria[J]. Braz J Microbiol, 2019, 50(1): 117-125.
[3] Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures[J]. Clin Infect Dis, 2021, 73(9): e2829-e2830.
[4] 夏薇, 韦红. 新生儿呼吸道合胞病毒感染及预防研究现状[J]. 儿科药学杂志, 2022, 28(3): 56-58.
[5] Breton MC, Lachance J, Aubin MC, et al. The effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus infections in children: a systematic review[M]. Institut National D'excellence en Santé Et en Services Sociaux, 2017.
[6] Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development[J]. Front Immunol, 2019, 10: 1675.
[7] Perico N, Cortinovis M, Suter F, et al. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents[J]. Lancet Infect Dis, 2023, 23(1): e22-e33.
[8] Kräutler NJ, Suan D, Butt D, et al. Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells[J]. J Exp Med, 2017, 214(5): 1259-1267.
[9] Bhoj VG, Arhontoulis D, Wertheim G, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy[J]. Blood, 2016, 128(3): 360-370.
[10] Brown BK. Regulation of the B cell antigen receptor trafficking to the peptide loading compartment[M]. University of Maryland, College Park, 2002.
[11] Gottwick C, He XC, Hofmann A, et al. A symmetric geometry of transmembrane domains inside the B cell antigen receptor complex[J]. Proc Natl Acad Sci USA, 2019, 116(27): 13468-13473.
[12] Oh KK, Adnan M, Cho DH. Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19[J]. Sci Rep, 2021, 11(1): 9606.
[13] 史红娟, 李群锋, 赵华, 等. 舒林酸抗肿瘤作用的研究进展[J]. 医学信息, 2018, 31(12): 35-38, 42.
[14] Maniewska J, Jez·ewska D. Non-steroidal anti-inflammatory drugs in colorectal cancer chemoprevention[J]. Cancers, 2021, 13(4): 594.
[15] Vishwakarma RK, Negi DS. The development of COX-1 and COX-2 inhibitors: a review[J]. Int J Pharm Sci Res, 2020, 11(8): 3544.
[16] Tanaka A, Araki H, Hase S, et al. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury[J]. Aliment Pharmacol Ther, 2002, 16(Suppl 2): 90-101.
[17] Yu JS, Chen WC, Tseng CK, et al. Sulforaphane suppresses hepatitis C virus replication by up-regulating heme oxygenase-1 expression through PI3K/Nrf2 pathway[J]. PLoS One, 2016, 11(3): e0152236.
[18] Docherty MJ, Jones RC 3rd, Wallace MS. Managing pain in inflammatory bowel disease[J]. Gastroenterol Hepatol, 2011, 7(9): 592-601.
[19] Ray N, Bisher ME, Enquist LW. Cyclooxygenase-1 and-2 are required for production of infectious pseudorabies virus[J]. J Virol, 2004, 78(23): 12964-12974.
[20] Lázár B, Brenner GB, Makkos A, et al. Lack of small intestinal dysbiosis following long-term selective inhibition of cyclooxygenase-2 by rofecoxib in the rat[J]. Cells, 2019, 8(3): 251.
[21] Gan TJ. Diclofenac: an update on its mechanism of action and safety profile[J]. Curr Med Res Opin, 2010, 26(7): 1715-1731.
